Mitsuyuki Matsumoto

Scientific Founder & Chief Scientific Officer

Relay Therapeutics Inc

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Mitsuyuki Matsumoto serves as the Scientific Founder and Chief Scientific Officer at Arialys Therapeutics, Inc., in the United States. His research focuses on innovative therapeutic approaches for neuropsychiatric disorders, particularly anti-NMDAR encephalitis and schizophrenia. Recent articles highlight advancements in antibody therapies and the biochemical mechanisms underlying various behavioral abnormalities.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (2)

Mitsuteru Nakamura

Project Junior Associate Professor

Kanagawa University of Human Services

JAPAN

View details

Shinichi Tokuno

University of Tokyo

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mitsuyuki Matsumoto

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

IND-Enabling Safety Studies for ART5803, a Clinical-Stage Therapeutic One-Armed Antibody to Treat Anti-NMDA Receptor Encephalitis (S7.004)

Novel Semi-Quantitative High Sensitivity ELISA for Detecting Anti-NMDA Receptor Autoantibodies in Serum and CSF (P1-8.013)

Peripherally Administered Therapeutic One-armed Antibody Reversed Behavioral Abnormalities in a Marmoset Model of Anti-NMDAR Encephalitis (S4.004)

Monoclonal Humanized One-Armed Antibody Blocking Therapy for Anti-NMDAR Encephalitis (S22.005)

Increased levels of a pro-inflammatory IgG receptor in the midbrain of people with schizophrenia

5-HT5A Receptor Antagonist ASP5736 Ameliorates Several Abnormal Behaviors in an <i>Fmr1-</i>Targeted Transgenic Male Rat Model of Fragile X Syndrome

Calcium/calmodulin-dependent protein kinase IIα heterozygous knockout mice show electroencephalogram and behavioral changes characteristic of a subpopulation of schizophrenia and intellectual impairment

Computational identification of variables in neonatal vocalizations predictive for postpubertal social behaviors in a mouse model of 16p11.2 deletion

Nuclear factor kappa B activation appears weaker in schizophrenia patients with high brain cytokines than in non-schizophrenic controls with high brain cytokines

Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome

Collaborators (2)

Mitsuteru Nakamura

Shinichi Tokuno

Make your next move.